Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | UQCRB | P14927 | 2/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.65 |
| ▸ | DDX3X | O00571 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296987 | 0.86 | GAA (0.93) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL7085112 | 0.86 | GAA (0.75) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL752345 | 0.85 | GAA (0.80) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL3260803 | 0.83 | GAA (0.71) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL3259826 | 0.83 | GAA (1.00) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL7574096 | 0.83 | MEN1 (0.71) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL1348234 | 0.83 | LMNA (0.75) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL17978501 | 0.82 | POLB (0.62) | KMT2AGAAMEN1HTTMAPT | |
| SCHEMBL3779868 | 0.81 | CA1 (1.00) | KMT2AHTTCA1CA2CA9 | |
| SCHEMBL3188254 | 0.81 | GAA (0.69) | KMT2AGAAMEN1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| EP-3432881-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| EP-3256461-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017162834-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
| US-RE38531-E1 | ANIONIC DYES; VERY INTENSE DARK SHADES FOR LEATHER | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-06-08 | — | — | US | disclosed |
| CN-1104470-C | Tetrakisazo dyes, their production and use | CLARIANT FINANCE BVI LTD (VG) | 2003-04-02 | — | — | CN | disclosed |
| EP-0931109-B1 | TETRAKISAZO DYES, THEIR PRODUCTION AND USE | CLARIANT FINANCE BVI LTD (VG) | 2003-02-26 | — | — | EP | disclosed |
| US-6043349-A | Tetrakisazo dyes, their production and use | CLARIANT FINANCE (BVI) LIMITED (VG) | 2000-03-28 | — | — | US | disclosed |
| CN-1236379-A | Tetrakisazo dyes, their production and use | CLARIANT FINANCE BVI LTD (GB) | 1999-11-24 | — | — | CN | disclosed |
| EP-0931109-A1 | TETRAKISAZO DYES, THEIR PRODUCTION AND USE | Clariant Finance (BVI) Limited (VG) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998010021-A1 | TETRAKISAZO DYES, THEIR PRODUCTION AND USE | CLARIANT FINANCE (BVI) LIMITED (VG) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | KMT2A 1704/4885GAA 2503/4885MEN1 3110/4885 |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | KMT2A 2343/4885GAA 1584/4885MEN1 3482/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | KMT2A 2343/4885GAA 1584/4885MEN1 3482/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | KMT2A 2343/4885GAA 1584/4885MEN1 3482/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | KMT2A 1644/4885GAA 2407/4885MEN1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.